Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren’s syndrome
The present study aimed at investigating whether the hydroxychloroquine (HCQ) treatment would impact the neutralizing antibody production, viremia levels and the kinetics of serum soluble mediators upon planned 17DD-Yellow Fever (YF) primovaccination (Bio-Manguinhos-FIOCRUZ) of primary Sjögren’s syn...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2318814 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849762884879384576 |
|---|---|
| author | Ketty Lysie Libardi Lira Machado Ismael Artur da Costa-Rocha Laura Gonçalves Rodrigues Aguiar Isac Ribeiro Moulaz Samira Tatiyama Miyamoto Priscila Costa Martins Erica Vieira Serrano Ana Paula Espíndula Gianordoli Maria da Penha Gomes Gouvea Maria de Fatima Bissoli Sheila Maria Barbosa de Lima Waleska Dias Schwarcz Adriana de Souza Azevedo Juliana Fernandes Amorim da Silva Renata Tourinho Santos Joaquim Pedro Brito-de-Sousa Jordana Grazziela Coelho-dos-Reis Ana Carolina Campi-Azevedo Andréa Teixeira-Carvalho Vanessa Peruhype-Magalhães Francieli Fontana Sutile Tardetti Fantinato Licia Maria Henrique da Mota Olindo Assis Martins-Filho Valéria Valim |
| author_facet | Ketty Lysie Libardi Lira Machado Ismael Artur da Costa-Rocha Laura Gonçalves Rodrigues Aguiar Isac Ribeiro Moulaz Samira Tatiyama Miyamoto Priscila Costa Martins Erica Vieira Serrano Ana Paula Espíndula Gianordoli Maria da Penha Gomes Gouvea Maria de Fatima Bissoli Sheila Maria Barbosa de Lima Waleska Dias Schwarcz Adriana de Souza Azevedo Juliana Fernandes Amorim da Silva Renata Tourinho Santos Joaquim Pedro Brito-de-Sousa Jordana Grazziela Coelho-dos-Reis Ana Carolina Campi-Azevedo Andréa Teixeira-Carvalho Vanessa Peruhype-Magalhães Francieli Fontana Sutile Tardetti Fantinato Licia Maria Henrique da Mota Olindo Assis Martins-Filho Valéria Valim |
| author_sort | Ketty Lysie Libardi Lira Machado |
| collection | DOAJ |
| description | The present study aimed at investigating whether the hydroxychloroquine (HCQ) treatment would impact the neutralizing antibody production, viremia levels and the kinetics of serum soluble mediators upon planned 17DD-Yellow Fever (YF) primovaccination (Bio-Manguinhos-FIOCRUZ) of primary Sjögren’s syndrome (pSS). A total of 34 pSS patients and 23 healthy controls (HC) were enrolled. The pSS group was further categorized according to the use of HCQ (HCQ and Non-HCQ). The YF-plaque reduction neutralization test (PRNT ≥1:50), YF viremia (RNAnemia) and serum biomarkers analyses were performed at baseline and subsequent time-points (Day0/Day3–4/Day5–6/Day7/Day14-D28). The pSS group showed PRNT titers and seropositivity rates similar to those observed for HC (GeoMean = 238 vs 440, p = .11; 82% vs 96%, p = .13). However, the HCQ subgroup exhibited lower seroconversion rates as compared to HC (GeoMean = 161 vs 440, p = .04; 69% vs 96%, p = .02) and Non-HQC (GeoMean = 161 vs 337, p = .582; 69% vs 94%, p = .049). No differences in YF viremia were observed amongst subgroups. Serum biomarkers analyses demonstrated that HCQ subgroup exhibited increased levels of CCL2, CXL10, IL-6, IFN-γ, IL1-Ra, IL-9, IL-10, and IL-2 at baseline and displayed a consistent increase of several biomarkers along the kinetics timeline up to D14–28. These results indicated that HCQ subgroup exhibited a deficiency in assembling YF-specific immune response elicited by 17DD-YF primovaccination as compared to Non-HCQ subgroup. Our findings suggested that hydroxychloroquine is associated with a decrease in the humoral immune response after 17DD-YF primovaccination. |
| format | Article |
| id | doaj-art-97db45a1ff164dbab861ba27016860e4 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-97db45a1ff164dbab861ba27016860e42025-08-20T03:05:35ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2318814Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren’s syndromeKetty Lysie Libardi Lira Machado0Ismael Artur da Costa-Rocha1Laura Gonçalves Rodrigues Aguiar2Isac Ribeiro Moulaz3Samira Tatiyama Miyamoto4Priscila Costa Martins5Erica Vieira Serrano6Ana Paula Espíndula Gianordoli7Maria da Penha Gomes Gouvea8Maria de Fatima Bissoli9Sheila Maria Barbosa de Lima10Waleska Dias Schwarcz11Adriana de Souza Azevedo12Juliana Fernandes Amorim da Silva13Renata Tourinho Santos14Joaquim Pedro Brito-de-Sousa15Jordana Grazziela Coelho-dos-Reis16Ana Carolina Campi-Azevedo17Andréa Teixeira-Carvalho18Vanessa Peruhype-Magalhães19Francieli Fontana Sutile Tardetti Fantinato20Licia Maria Henrique da Mota21Olindo Assis Martins-Filho22Valéria Valim23Programa de Pós-Graduação em Saúde Coletiva (PPGSC) and Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES/EBSERH)Grupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, BrazilPrograma de Pós-Graduação em Saúde Coletiva (PPGSC) and Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES/EBSERH)Programa de Pós-Graduação em Saúde Coletiva (PPGSC) and Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES/EBSERH)Programa de Pós-Graduação em Saúde Coletiva (PPGSC) and Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES/EBSERH)Programa de Pós-Graduação em Saúde Coletiva (PPGSC) and Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES/EBSERH)Programa de Pós-Graduação em Saúde Coletiva (PPGSC) and Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES/EBSERH)Programa de Pós-Graduação em Saúde Coletiva (PPGSC) and Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES/EBSERH)Programa de Pós-Graduação em Saúde Coletiva (PPGSC) and Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES/EBSERH)Programa de Pós-Graduação em Saúde Coletiva (PPGSC) and Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES/EBSERH)Departamento de Desenvolvimento Experimental e Pré-clínico (DEDEP), Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, BrazilLaboratório de Análise Imunomolecular (LANIM), Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, BrazilLaboratório de Análise Imunomolecular (LANIM), Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, BrazilLaboratório de Análise Imunomolecular (LANIM), Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, BrazilLaboratório de Tecnologia Virológica (LATEV), Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, BrazilGrupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, BrazilLaboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilGrupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, BrazilGrupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, BrazilGrupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, BrazilDepartamento de Vigilância das Doenças Transmissíveis, Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasília, BrazilServiço de Reumatologia do Hospital Universitário de Brasília, Programa de Pós-graduação em Ciências Médicas, Faculdade de Medicina, Universidade de Brasília, Brasília, BrazilGrupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, BrazilPrograma de Pós-Graduação em Saúde Coletiva (PPGSC) and Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES/EBSERH)The present study aimed at investigating whether the hydroxychloroquine (HCQ) treatment would impact the neutralizing antibody production, viremia levels and the kinetics of serum soluble mediators upon planned 17DD-Yellow Fever (YF) primovaccination (Bio-Manguinhos-FIOCRUZ) of primary Sjögren’s syndrome (pSS). A total of 34 pSS patients and 23 healthy controls (HC) were enrolled. The pSS group was further categorized according to the use of HCQ (HCQ and Non-HCQ). The YF-plaque reduction neutralization test (PRNT ≥1:50), YF viremia (RNAnemia) and serum biomarkers analyses were performed at baseline and subsequent time-points (Day0/Day3–4/Day5–6/Day7/Day14-D28). The pSS group showed PRNT titers and seropositivity rates similar to those observed for HC (GeoMean = 238 vs 440, p = .11; 82% vs 96%, p = .13). However, the HCQ subgroup exhibited lower seroconversion rates as compared to HC (GeoMean = 161 vs 440, p = .04; 69% vs 96%, p = .02) and Non-HQC (GeoMean = 161 vs 337, p = .582; 69% vs 94%, p = .049). No differences in YF viremia were observed amongst subgroups. Serum biomarkers analyses demonstrated that HCQ subgroup exhibited increased levels of CCL2, CXL10, IL-6, IFN-γ, IL1-Ra, IL-9, IL-10, and IL-2 at baseline and displayed a consistent increase of several biomarkers along the kinetics timeline up to D14–28. These results indicated that HCQ subgroup exhibited a deficiency in assembling YF-specific immune response elicited by 17DD-YF primovaccination as compared to Non-HCQ subgroup. Our findings suggested that hydroxychloroquine is associated with a decrease in the humoral immune response after 17DD-YF primovaccination.https://www.tandfonline.com/doi/10.1080/21645515.2024.2318814Primary Sjögren’s syndromehydroxychloroquine17DD-YF vaccinehumoral immunityserum biomarkers |
| spellingShingle | Ketty Lysie Libardi Lira Machado Ismael Artur da Costa-Rocha Laura Gonçalves Rodrigues Aguiar Isac Ribeiro Moulaz Samira Tatiyama Miyamoto Priscila Costa Martins Erica Vieira Serrano Ana Paula Espíndula Gianordoli Maria da Penha Gomes Gouvea Maria de Fatima Bissoli Sheila Maria Barbosa de Lima Waleska Dias Schwarcz Adriana de Souza Azevedo Juliana Fernandes Amorim da Silva Renata Tourinho Santos Joaquim Pedro Brito-de-Sousa Jordana Grazziela Coelho-dos-Reis Ana Carolina Campi-Azevedo Andréa Teixeira-Carvalho Vanessa Peruhype-Magalhães Francieli Fontana Sutile Tardetti Fantinato Licia Maria Henrique da Mota Olindo Assis Martins-Filho Valéria Valim Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren’s syndrome Human Vaccines & Immunotherapeutics Primary Sjögren’s syndrome hydroxychloroquine 17DD-YF vaccine humoral immunity serum biomarkers |
| title | Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren’s syndrome |
| title_full | Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren’s syndrome |
| title_fullStr | Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren’s syndrome |
| title_full_unstemmed | Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren’s syndrome |
| title_short | Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren’s syndrome |
| title_sort | hydroxychloroquine is associated with lower seroconversion upon 17dd yellow fever primovaccination in patients with primary sjogren s syndrome |
| topic | Primary Sjögren’s syndrome hydroxychloroquine 17DD-YF vaccine humoral immunity serum biomarkers |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2318814 |
| work_keys_str_mv | AT kettylysielibardiliramachado hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT ismaelarturdacostarocha hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT lauragoncalvesrodriguesaguiar hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT isacribeiromoulaz hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT samiratatiyamamiyamoto hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT priscilacostamartins hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT ericavieiraserrano hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT anapaulaespindulagianordoli hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT mariadapenhagomesgouvea hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT mariadefatimabissoli hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT sheilamariabarbosadelima hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT waleskadiasschwarcz hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT adrianadesouzaazevedo hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT julianafernandesamorimdasilva hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT renatatourinhosantos hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT joaquimpedrobritodesousa hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT jordanagrazzielacoelhodosreis hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT anacarolinacampiazevedo hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT andreateixeiracarvalho hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT vanessaperuhypemagalhaes hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT francielifontanasutiletardettifantinato hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT liciamariahenriquedamota hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT olindoassismartinsfilho hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome AT valeriavalim hydroxychloroquineisassociatedwithlowerseroconversionupon17ddyellowfeverprimovaccinationinpatientswithprimarysjogrenssyndrome |